Skip to main content
. 2016 Jul 11;22(8):1870–1880. doi: 10.1097/MIB.0000000000000805

FIGURE 4.

FIGURE 4.

Relationship of certolizumab pegol ADAb status with certolizumab pegol concentrations and immunomodulator use. A, Cumulative proportion of certolizumab pegol ADAb-positive patients by immunomodulator use at baseline. B, Geometric mean concentrations of certolizumab pegol over time by ADAb status. Error bars indicate 95% CIs.